Integrative Cancer Scholars Training Grant
Integrative Cancer Scholars Training Grant
批准号:
10680574
负责人:
Jennifer S Carew
金额:
$26.36万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1983
资助国家:
美国
项目状态:
未结题
起止时间:
1983-09-01 至 2025-08-31
中文摘要
摘要
我们的目标是招募、培训和发展下一代癌症研究领域的领导者。要做到这一点
目标,我们将实施整合癌症学者(ICS)计划,如本竞赛中所述
更新我们长期的癌症生物学培训计划。ICS是一名创新的博士后和
博士后研究员培训计划,采用结对导师团队的方法,以最大限度地发挥影响
以及癌症研究的意义。具体来说,学者们选择一名基础科学导师和一名临床导师
来自全国有竞争力的基础和内科科学家的科学导师。从导师对中,
SCARTER从拥有资金充足的合作研究项目的教职员工中选择一位首席导师
广泛的癌症研究专业:基因组和表观遗传不稳定性,肿瘤微环境,
癌症预防和控制、发展治疗学、癌症成像、肿瘤病毒和
免疫学、肿瘤进展和转移,以及癌症疼痛。ICS是一个独特的计划,具有独特的
旨在整合当前分子和临床癌症概念的培训活动。每一位学者都希望
在导师对的指导下进行原创前沿研究并参与临床
案例与他们选择的医生导师。通过强制性委员会确保每个实习生的进步
两位导师的会议和年度评估。学者也参与职业发展和
国家网络机会,包括在我们的癌症生物学研讨会系列中接待思想领袖,
在教育研讨会中获得新的有针对性的技能,以及与肿瘤学家和
生物技术专家。此外,还为奖学金获得者提供旅行支持,并在国家
开会。ICS与癌症生物学研究生跨学科项目有关,该项目提供
在癌症病因、流行病学、预防方面的指导,以及通过特定的课程和
以博士后和博士后研究报告为特色的研讨会。博士后培训计划确保
确保每个学员都能走上一条综合培训之路,从而获得成熟的学识和能力
进行独立的、前沿的研究。该计划旨在让每个实习生接触到以下范围的
当前癌症领域的思想,教授最先进的实验室技术,强调批判性思维
技能,介绍临床工作的实际方面,并完善他们的职业发展技能,特别是
在网络、通信和赠款/手稿准备方面。来自美国的博士后和博士后研究员
参与导师的实验室有资格获得ICS支持,并通过
竞争过程。来自UA的支持,最先进的研究核心设施,以及
代表性不足的少数族裔研究人员(UA是研究生院所有URM研究机构中的佼佼者)
为培养未来的癌症研究带头人提供丰富的环境。
英文摘要
Abstract
Our goal is to recruit, train and develop the next generation of leaders in cancer research. To achieve this
objective, we will implement the Integrative Cancer Scholars (ICS) program as described in this competitive
renewal of our long-standing Cancer Biology Training Program. ICS is an innovative predoctoral and
postdoctoral fellows training program that embraces a paired-mentor team approach to maximize the impact
and significance of cancer research. Specifically, Scholars choose one basic science mentor and one clinical
science mentor from among nationally competitive basic and physician scientists. From the mentor pair, the
Scholar selects a `lead' mentor from among the faculty with well-funded collaborative research programs with a
broad range of cancer research specialties: Genomic and Epigenetic Instability, Tumor Microenvironment,
Cancer Prevention and Control, Developmental Therapeutics, Cancer Imaging, Tumor Viruses and
Immunology, Tumor Progression and Metastasis, and Cancer Pain. ICS is a unique program with distinct
training events designed to integrate current molecular and clinical cancer concepts. Each Scholar is expected
to conduct original cutting-edge research under the guidance of the mentor-pair and to participate in clinical
cases with their chosen physician mentor. Progress of each trainee is ensured through compulsory committee
meetings and annual evaluations by the mentor-pair. Scholars also participate in career development and
national networking opportunities, including hosting thought leaders in our Cancer Biology Seminar Series,
acquiring new targeted skills in educational workshops, and community engagement with oncologists and
biotechnology experts. Additionally, Scholars are provided support to travel and present their work at a national
meeting. ICS is associated with the Cancer Biology Graduate Interdisciplinary Program which provides
instruction in cancer causation, epidemiology, prevention, and grant writing through specific coursework and a
symposium featuring presentations of pre- and postdoctoral research. The postdoctoral training plan ensures
that each trainee navigates a path of comprehensive training, leading to a mature scholarship and ability to
conduct independent, cutting-edge research. The program is designed to expose each trainee to the range of
current thought in the cancer field, to teach state-of-the-art laboratory techniques, to emphasize critical thinking
skills, to introduce real-world aspects of clinical work, and to refine their career-development skills, particularly
in networking, communication and grant/manuscript preparation. Pre- and postdoctoral researchers from
laboratories of the participating mentors are eligible for ICS support, and Scholars are selected through a
competitive process. Support from the UA, state-of-the-art research core facilities, and opportunities for
underrepresented-minority researchers (UA is top of all Research I institutions for URMs in graduate school)
round out a rich environment for training the future leaders of cancer research.
期刊论文(69)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Determination of spirogermanium (2-aza-8-germanspiro[4.5]-decane-2-propanamine-8,8-diethyl-N,N-dimethyl dichloride) by fluorometric ion-pair extraction. Application to the uniformity of content of solutions for intravenous injection.
通过荧光离子对萃取法测定螺锗(2-氮杂-8-germanspiro[4.5]-癸烷-2-丙胺-8,8-二乙基-N,N-二甲基二氯)。
DOI:
10.1016/0731-7085(89)80106-2
发表时间:
1989
期刊:
Journal of pharmaceutical and biomedical analysis
影响因子:
3.4
作者:
[Riley,CM, Monnot,EA, Stobaugh,JF, Slavik,M]
通讯作者:
Slavik,M
Expression of beta-actin during progression of mouse skin tumors.
小鼠皮肤肿瘤进展过程中β-肌动蛋白的表达。
DOI:
10.1093/carcin/10.8.1439
发表时间:
1989
期刊:
Carcinogenesis
影响因子:
4.7
作者:
[Ostrowski,LE, Krieg,P, Finch,J, Cress,AE, Nagle,RB, Bowden,GT]
通讯作者:
Bowden,GT
Expression of the EVI1 gene in chronic myelogenous leukemia in blast crisis.
EVI1基因在慢性粒细胞白血病急变期的表达。
DOI:
--
发表时间:
1993
期刊:
Leukemia
影响因子:
11.4
作者:
[Russell,M, Thompson,F, Spier,C, Taetle,R]
通讯作者:
Taetle,R
B7-1 amplifies the response to interleukin-2-secreting tumor vaccines in vivo, but fails to induce a response by naive cells in vitro.
B7-1 可在体内增强对分泌白细胞介素 2 的肿瘤疫苗的反应,但无法在体外诱导幼稚细胞的反应。
DOI:
10.1089/hum.1995.6.10-1299
发表时间:
1995
期刊:
Human gene therapy
影响因子:
4.2
作者:
[Salvadori,S, Gansbacher,B, Wernick,I, Tirelli,S, Zier,K]
通讯作者:
Zier,K
A DNA polymerase alpha-associated 56 kDa protein kinase.
一种 DNA 聚合酶 α 相关的 56 kDa 蛋白激酶。
DOI:
10.1006/bbrc.1993.1051
发表时间:
1993
期刊:
Biochemical and biophysical research communications
影响因子:
3.1
作者:
[Peck,VM, Gerner,EW, Cress,AE]
通讯作者:
Cress,AE
共 52 条
Targeting Lysosomal Vulnerabilities in Renal Pathogenesis
-
批准号:10570295
-
项目类别:
-
资助金额:$47.12万
-
财政年份:2022
-
负责人:Jennifer S Carew
-
依托单位:
Development of lysosome targeted therapeutics
-
批准号:10482643
-
项目类别:
-
资助金额:$25.83万
-
财政年份:2022
-
负责人:Jennifer S Carew
-
依托单位:
Targeting NEDD8-Mediated Protein Turnover in AML
-
批准号:8632457
-
项目类别:
-
资助金额:$30.88万
-
财政年份:2014
-
负责人:Jennifer S Carew
-
依托单位:
Targeting NEDD8-Mediated Protein Turnover in AML
-
批准号:8845524
-
项目类别:
-
资助金额:$8.83万
-
财政年份:2014
-
负责人:Jennifer S Carew
-
依托单位:
Targeting NEDD8-Mediated Protein Turnover in AML
-
批准号:9310390
-
项目类别:
-
资助金额:$28.67万
-
财政年份:2014
-
负责人:Jennifer S Carew
-
依托单位:
海外基金